• In February 2026, Humana reported fourth-quarter 2025 revenue of US$32,515 million and a net loss of US$796 million, while issuing 2026 GAAP EPS guidance of at least US$8.89 and highlighting ongoing Medicare Advantage and operational pressures.
• Amid this, Humana advanced its longer-term plans through AI-powered call-center tools with Google Cloud, a new provider agreement with Zynex, and CenterWell’s acquisition of MaxHealth to expand value-based primary care.
• We’ll now examine how Humana’s more cautious 2026 earnings outlook, especially around Medicare Advantage profitability, reshapes the company’s investment narrative.

Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

Humana Investment Narrative Recap

To own Humana today, you have to believe that its Medicare Advantage scale, CenterWell platform and technology investments can offset reimbursement pressure and earnings volatility. The latest results and below-consensus 2026 EPS guidance keep the near term earnings recovery as the key catalyst, while the biggest risk remains Medicare Advantage profitability, given funding proposals and Star ratings uncertainty. These updates appear material for how quickly, and how confidently, that earnings story might improve.

Among recent announcements, the rollout of Agent Assist with Google Cloud looks most directly tied to that earnings catalyst. With tens of millions of member calls each year, even modest gains in call accuracy, member experience and advocate productivity can matter for administrative costs and retention. For investors watching margins and service quality in Medicare Advantage, execution on this AI initiative now sits more squarely in the spotlight.

Yet beneath these long term opportunities, investors should also be aware that Humana’s heavy reliance on Medicare Advantage reimbursement creates...

Humana's narrative projects $150.9 billion revenue and $3.3 billion earnings by 2028.

Uncover how Humana's forecasts yield a $287.38 fair value, a 56% upside to its current price.

Exploring Other Perspectives

Before this earnings miss, the most optimistic analysts were assuming revenue could reach about US$157 billion and earnings US$3.1 billion, a far smoother path than today’s Medicare Advantage and Stars uncertainty suggests, so it is worth asking how that more upbeat story fits with growing concern about reimbursement risk.

Explore 11 other fair value estimates on Humana - why the stock might be worth just $199.74!

Build Your Own Humana Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Humana research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.